tbuckley/cabot-search huggingface dataset:
Partial knee replacement could be first choice for some patients with osteoarthritis
Authors: Rob Cook, Peter Davidson, Alicia White
Journal: BMJ (2019)

The study Beard D, Davies L, Cook J, et al. The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. Lancet 2019;394:746-56. The study was funded by the NIHR Health Technology Assessment Programme (project number 08/14/08). To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000824/partial-knee-replacement-could-be-first-choice-in-some-patients
AB0012 Urine and plasma interleukin-6 (il-6) levels in patients with glomerular disease
Authors: D Soldo-Jure?a, D Vergles, MI Èulo, K Gale?iæ
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> IL-6 is involved in the induction of acute phase protein synthesis in liver cells, as well as in other systemic changes associated with infection and tissue injury. IL-6 is probably produced by mesangial cells in patients with mesangial proliferative glomerulonephritis (MPG). <h3>Objectives</h3> The aim of this study was to determine IL-6 levels in urine and plasma of patients with primary glomerular disease ? MPG and of patients with systemic lupus erythematosus who had MPG (II class of lupus nephritis according to WHO). <h3>Methods</h3> The study included 23 patients and 10 healthy volunteers. 12 out 23 patients had MPG and 6 had SLE and MPG. 5 out 23 patients had membranoproliferative glomerulonephritis. Plasma and urine IL-6 levels were determined using sensitive bioassay. <h3>Results</h3> Measurable quantities of IL-6 were detected in the urine (mean ± SEM = 24.75 ± 0.61 pg/ml; n = 10) as well as in the plasma (14.18 ± 0.43 pg/ml; n = 10) of healthy controls. Increased urine IL-6 levels were found in patients with primary and secondary (with SLE) MPG (29.75 ± 0.75; n = 17; p &lt; 0.01), while in patients with membranoproliferative glomerulonephritis the IL-6 concentration did not differ from the control values (25.24 ± 1.4; n = 5; p &gt; 0.05). In plasma the mean IL-6 concentration in patients with MPG and SLE was slightly but not significantly higher than in the healthy subjects. <h3>Conclusion</h3> The data show that the presence of IL-6 in urine but not in plasma, may be a valuable indication of the disease in the majority of patients with primary MPG and patients with SLE who had MPG.
Disparities in Access to Oral Health Care
Authors: Mary E. Northridge, Anjali Kumar, Raghbir Kaur
Journal: Annual Review of Public Health (2020)

In the United States, people are more likely to have poor oral health if they are low-income, uninsured, and/or members of racial/ethnic minority, immigrant, or rural populations who have suboptimal access to quality oral health care. As a result, poor oral health serves as the national symbol of social inequality. There is increasing recognition among those in public health that oral diseases such as dental caries and periodontal disease and general health conditions such as obesity and diabetes are closely linked by sharing common risk factors, including excess sugar consumption and tobacco use, as well as underlying infection and inflammatory pathways. Hence, efforts to integrate oral health and primary health care, incorporate interventions at multiple levels to improve access to and quality of services, and create health care teams that provide patient-centered care in both safety net clinics and community settings may narrow the gaps in access to oral health care across the life course.
Cisplatin and capecitabine with and without docetaxel as a first-line chemotherapy in patients with metastatic gastric carcinoma: Single clinical experience.
Authors: Mekhty Narimanov, Alexey Tryakin, Varlam Zarkua, Igor Bazin, August Garin, Sergei Tjulandin
Journal: Journal of Clinical Oncology (2013)

e15194 Background: Cisplatin and capecitabine and docetaxel are active agents for treatment of metastatic gastric carcinoma. We underwent analysis of efficacy and toxicity of douplet (CX ) and triplet (DCX) regimens which were used in our department as a first-line chemotherapy in patients with metastatic gastric carcinoma. Methods: Pts with metastatic gastric carcinoma were nonrandomly allocated to DCX regimen (docetaxel 75 mg/m 2 i.v. day 1, cisplatin 75 mg/m 2 i.v. day 1, capecitabine 1650 mg/m 2 per os days 1-14) or CX regimen (cisplatin 75 mg/m 2 i.v. day 1, capecitabine 2000 mg/m 2 per os days 1-14 ). Up to 6 cycles were provided every 3 weeks. G-CSF was not routinely used for primary prophylaxis. Results: From 2008 to 2012 81 pts were included in the study (DCX – 37 pts, CX – 44 pts). Pts characteristics were similar in both groups (table 1). Median number of cycles in both groups was 5 (range, 1-6). Grade 3-4 toxicity (per cycle) in DCX and CX groups were neutropenia 24,9% and 16,1%, deep venous thrombosis – 2% and 0%, diarrhea – 6.2% and 7,4%, stomatitis – 3.8% and 2,2%, infection – 11% and 0%, anemia 14% and 13,5% pts, respectively. No toxic deaths were observed. Median progression-free survival (PFS) in DCX and CX were 7,5 months (95% CI 6,1-8,9) and 5,4 months (95% CI 5,0-6,2; p=0.0009), median overall survival (OS) 14,5 months (95% CI 10,1-18,9) and 9,3 months (95% CI 9,2-10,2; p=0.0018), respectively. Conclusions: Addition of docetaxel to the combination of cisplatin and capecitabine associates with significant improvement of PFS and OS. Higher rate of infection requires use of G-CSF in primary prophylaxis. [Table: see text]
Priming recognition memory test cues: No evidence for an attributional basis of recollection
Authors: Carmen F Ionita, Deborah Talmi, Jason R Taylor
Journal: Behavioral and Brain Sciences (2019)

Abstract We argue that while the proposed memory model by Bastin et al. can explain familiarity-based memory judgements through the interaction of a core representation system and an attribution system, recollection-based memory judgements are not based on non-mnemonic signals being attributed to memory.
Sphingolipids in Alzheimer's disease, how can we target them?
Authors: Simone M. Crivelli, Caterina Giovagnoni, Lars Visseren, Anna-Lena Scheithauer, Nienke de Wit, Sandra den Hoedt, Mario Losen, Monique T. Mulder, Jochen Walter, Helga E. de Vries, Erhard Bieberich, Pilar Martinez-Martinez
Journal: Advanced Drug Delivery Reviews (2020)
A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways
Authors: Yanjuan Huang, Zhanghong Xiao, Zilin Guan, Yifeng Shen, Yali Jiang, Xiaoyu Xu, Zeqian Huang, Chunshun Zhao
Journal: Journal of Controlled Release (2019)
Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting
Authors: Hideaki Uchida, Masahiro Kamata, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi, Yayoi Tada
Journal: Journal of the American Academy of Dermatology (2019)
Characterization of Parylene-C degradation mechanisms: In vitro reactive accelerated aging model compared to multiyear in vivo implantation
Authors: Ryan Caldwell, Matthew G. Street, Rohit Sharma, Pavel Takmakov, Brian Baker, Loren Rieth
Journal: Biomaterials (2019)

Implantable neural microelectrodes are integral components of neuroprosthetic technologies and can transform treatments for many neural-mediated disorders. However, dielectric material degradation during long-term (>1 year) indwelling periods restricts device functional lifetimes to a few years. This comprehensive work carefully investigates in vivo material degradation and also explores the ability of in vitro Reactive Accelerated Aging (RAA) to evaluate implant stability. Parylene C-coated Utah electrode arrays (UEAs) implanted in feline peripheral nerve for 3.25 years were explanted and compared to RAA-processed devices, aged in phosphate buffered saline (PBS) + 20 mM H2O2 at either 67 or 87 °C (28 or 7 days, respectively). Electron microscopy revealed similar physical damage characteristics between explants and RAA (87 °C) devices. Parylene C degradation was overwhelmingly apparent for UEAs from both RAA cohorts. Controls aged in PBS alone displayed almost no damage. Spectroscopic characterization (EDX, XPS, FTIR) found clear indications of oxidation and chlorine abstraction for Parylene C aged in vivo. While in vitro aging was also accompanied by signs of oxidation, changes in the chemistry in vivo and in vitro were statistically different. Analysis of RAA-aged devices identified UEA fabrication approaches that may greatly improve device resistance to degradation. This work underscores the need for an improved understanding of in vivo damage mechanisms, to facilitate the critical need for representative in vitro accelerated testing paradigms for long-term implants.
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
Authors: Kasiani C Myers, Elissa Furutani, Edie Weller, Bradford Siegele, Ashley Galvin, Valerie Arsenault, Blanche P Alter, Farid Boulad, Carlos Bueso-Ramos, Lauri Burroughs, Paul Castillo, James Connelly, Stella M Davies, Courtney D DiNardo, Iftikhar Hanif, Richard H Ho, Nicole Karras, Michelle Manalang, Lisa J McReynolds, Taizo A Nakano, Grzegorz Nalepa, Maxim Norkin, Matthew J Oberley, Etan Orgel, Yves D Pastore, Joseph Rosenthal, Kelly Walkovich, Jordan Larson, Maggie Malsch, M Tarek Elghetany, Mark D Fleming, Akiko Shimamura
Journal: The Lancet Haematology (2019)
Getting Serious About Opioid Regulation
Authors: William K. Hubbard
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-κB Activation
Authors: Shekhar Saha, Manjari Kiran, Canan Kuscu, Ajay Chatrath, David Wotton, Marty W. Mayo, Anindya Dutta
Journal: Cancer Research (2020)

Abstract DRAIC is a 1.7 kb spliced long noncoding RNA downregulated in castration-resistant advanced prostate cancer. Decreased DRAIC expression predicts poor patient outcome in prostate and seven other cancers, while increased DRAIC represses growth of xenografted tumors. Here, we show that cancers with decreased DRAIC expression have increased NF-κB target gene expression. DRAIC downregulation increased cell invasion and soft agar colony formation; this was dependent on NF-κB activation. DRAIC interacted with subunits of the IκB kinase (IKK) complex to inhibit their interaction with each other, the phosphorylation of IκBα, and the activation of NF-κB. These functions of DRAIC mapped to the same fragment containing bases 701–905. Thus, DRAIC lncRNA inhibits prostate cancer progression through suppression of NF-κB activation by interfering with IKK activity. Significance: A cytoplasmic tumor-suppressive lncRNA interacts with and inhibits a major kinase that activates an oncogenic transcription factor in prostate cancer.
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis
Authors: Henry L. Danahay, Sarah Lilley, Roy Fox, Holly Charlton, Juan Sabater, Brian Button, Clive McCarthy, Stephen P. Collingwood, Martin Gosling
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Enhancing non–CFTR (cystic fibrosis transmembrane conductance regulator)-mediated anion secretion is an attractive therapeutic approach for the treatment of cystic fibrosis (CF) and other mucoobstructive diseases.Objectives: To determine the effects of TMEM16A potentiation on epithelial fluid secretion and mucociliary clearance.Methods: The effects of a novel low-molecular-weight TMEM16A potentiator (ETX001) were evaluated in human cell and animal models of airway epithelial function and mucus transport.Measurements and Main Results: Potentiating the activity of TMEM16A with ETX001 increased the Ca2+-activated Cl− channel activity and anion secretion in human bronchial epithelial (HBE) cells from patients with CF without impacting calcium signaling. ETX001 rapidly increased fluid secretion and airway surface liquid height in CF-HBE cells under both static conditions and conditions designed to mimic the shear stress associated with tidal breathing. In ovine models of mucus clearance (tracheal mucus velocity and mucociliary clearance), inhaled ETX001 was able to accelerate clearance both when CFTR function was reduced by administration of a pharmacological blocker and when CFTR was fully functional.Conclusions: Enhancing the activity of TMEM16A increases epithelial fluid secretion and enhances mucus clearance independent of CFTR function. TMEM16A potentiation is a novel approach for the treatment of patients with CF and non-CF mucoobstructive diseases.
Quality and Safety in Healthcare, Part LXII
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2019)

Abstract Multiple national organizations promote resident wellness. The Accreditation Council for Graduate Medical Education limits work hours and sleep deprivation for residents. The Accreditation Council for Graduate Medical Education requires that residency programs take into consideration the intensity of the work, how residents are scheduled, and that residents be given reasonable time off to go to medical and dental care appointments. The Action Collaborative on Clinician Well-Being and Resilience, the National Wellness Institute, the American Medical Association, and the American College of Radiology are some of the other national organizations fighting burnout and promoting wellness.
Emerging organoid models: leaping forward in cancer research
Authors: Han Fan, Utkan Demirci, Pu Chen
Journal: Journal of Hematology & Oncology (2019)

Abstract Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understanding cancer biology as well as for developing personalized anti-cancer therapy. Cancer organoids represent an emerging approach for creating patient-derived in vitro cancer models that closely recapitulate the pathophysiological features of natural tumorigenesis and metastasis. Meanwhile, cancer organoids have recently been utilized in the discovery of personalized anti-cancer therapy and prognostic biomarkers. Further, the synergistic combination of cancer organoids with organ-on-a-chip and 3D bioprinting presents a new avenue in the development of more sophisticated and optimized model systems to recapitulate complex cancer-stroma or multiorgan metastasis. Here, we summarize the recent advances in cancer organoids from a perspective of the in vitro emulation of natural cancer evolution and the applications in personalized cancer theranostics. We also discuss the challenges and trends in reconstructing more comprehensive cancer models for basic and clinical cancer research.
Poly(<scp>ADP</scp>‐Ribose) Polymerase Enhances Infiltration of Mononuclear Cells in Primary Sjögren's Syndrome Through Interferon‐Induced Protein With Tetratricopeptide Repeats 1–Mediated Up‐Regulation of <scp>CXCL</scp>10
Authors: Qingqing Tian, Han Zhao, Hanzhi Ling, Li Sun, Chipeng Xiao, Guoyu Yin, Xiaobing Wang, Gan Wu, Chenglin Yang, Mu Chen, Shengwei Jin, Xinyu Yang, Jianguang Wang
Journal: Arthritis & Rheumatology (2019)

Mononuclear cell infiltration and type I interferon (IFN) system activation play an important role in primary Sjögren's syndrome (SS). We undertook this study to investigate the mechanism of poly(ADP-ribose) polymerase family member 9 (PARP-9) on mononuclear cell infiltration triggered by type I IFN.A proteomic study was conducted in peripheral blood mononuclear cells from patients with primary SS (n = 30) and healthy controls (n = 30) to determine differentially expressed proteins (DEPs) (P < 0.05; fold change >1.20). Labial salivary glands (LSGs) were isolated for hematoxylin and eosin staining and immunohistochemical analysis. CD19+ B cells were purified by magnetic cell sorting for immunofluorescence staining, lentivirus-PARP-9 transfection, and IFNα treatment experiments. PARP-9 small interfering RNA (siRNA) and DTX3L siRNA were delivered into female NOD/LtJ female mice to determine their effect.The overexpression of PARP-9 and CXCL10 as well as their colocalization was confirmed in primary SS. PARP-9 levels in LSGs rose with increased Chisholm scores in patients with primary SS. PARP-9 and DTX3L were present in the infiltrating mononuclear cells from salivary glands in female NOD/LtJ mouse models. Additionally, Ingenuity Pathway Analysis networks of DEPs demonstrated that PARP-9, STAT1, and IFN-induced protein with tetratricopeptide repeats 1 (IFIT-1) participated in the IFN-related pathway. Furthermore, PARP-9 could up-regulate the expression of IFIT1 and CXCL10 in B cells. Moreover, PARP-9 and CXCL10 could be induced by IFNα in B cells.This study is the first to implicate PARP-9 as a regulator of infiltration of mononuclear cells in primary SS progression and to reveal that PARP-9 increases CXCL10 expression through up-regulating IFIT-1, which is mediated by the phosphorylation of STAT1. PARP-9 might therefore be a novel therapeutic target for primary SS.
Framing New Models to Expand Access to Radiotherapy in Limited Resource Settings—Social Entrepreneurship
Authors: Omoruyi C. Irabor, Benjamin C. Li, Oluwadamilola T. Oladeru
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p/MFN1 axis
Authors: Xiaofan Yang, Pingping Xue, Hongrui Chen, Meng Yuan, Yu Kang, Dominik Duscher, Hans-Günther Machens, Zhenbing Chen
Journal: Theranostics (2020)

Rationale: Peripheral nerve injury is common in clinic, which leads to severe atrophy and dysfunction of the denervated muscles, but the underlying mechanism is not fully understood. Recent studies advanced the causative role of mitochondrial dysfunction in muscle atrophy, while the upstream triggers remained unclear. Methods: In the present study, Atrophy of gastrocnemius and tibialis anterior (TA) were evaluated in mice sciatic nerve transection model. Transmission electron microscopy (TEM) was then used to observe the microstructure of atrophic gastrocnemius and mitochondria. Subsequently, small RNA sequencing, luciferase reporter assay and Electrophoretic Mobility Shift (EMSA) were performed to explore the potential signaling pathway involved in skeletal muscle atrophy. The effects of the corresponding pathway on mitochondrial function, mitophagy, apoptosis and muscle atrophy were further determined in C2C12 cells and denervated gastrocnemius. Results: Gastrocnemius and TA atrophied rapidly after denervation. Obvious decrease of mitochondria number and activation of mitophagy was further observed in atrophic gastrocnemius. Further, miR-142a-5p/ mitofusin-1 (MFN1) axis was confirmed to be activated in denervated gastrocnemius, which disrupted the tubular mitochondrial network, and induced mitochondrial dysfunction, mitophagy and apoptosis. Furthermore, the atrophy of gastrocnemius induced by denervation was relieved through targeting miR-142a-5p/MFN1 axis. Conclusions: Collectively, our data revealed that miR-142a-5p was able to function as an important regulator of denervation-induced skeletal muscle atrophy by inducing mitochondrial dysfunction, mitophagy, and apoptosis via targeting MFN1. Our findings provide new insights into the mechanism of skeletal muscle atrophy following denervation and propose a viable target for therapeutic intervention in individuals suffering from muscle atrophy after peripheral nerve injury.
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer
Authors: Huiyan Luo, Qi Zhao, Wei Wei, Lianghong Zheng, Shaohua Yi, Gen Li, Wenqiu Wang, Hui Sheng, Hengying Pu, Haiyu Mo, Zhixiang Zuo, Zexian Liu, Chaofeng Li, Chuanbo Xie, Zhaolei Zeng, Weimin Li, Xiaoke Hao, Yuying Liu, Sumei Cao, Wanli Liu, Sarah Gibson, Kang Zhang, Guoliang Xu, Rui-hua Xu
Journal: Science Translational Medicine (2020)

Circulating tumor DNA methylation–based signatures are potential biomarkers for early diagnosis and prognosis of colorectal cancer.